Alam et al. (2017) determined the ubiquitination of OATP1B1 and OATP1B3, one of the major mechanisms through which proteins are degraded intracellularly, and the apparent substrate-dependent inhibitory effect of proteosome inhibitor bortezomib, a drug used for multiple myeloma treatment, on OATP1B3-mediated transport [245]. The gene discussed is SLCO1B3; the disease is AL amyloidosis.